BACE1 and Alzheimer disease: Measurement of these substrate/activity‐based markers for BACE1 and BACE2 may help to dose BACE inhibitors in a safe and individualized manner, allowing precision therapies in future trials for AD prevention or to prevent reoccurrence of amyloid pathology after Aβ immunotherapy [4, 20].